CD4 and neoplasm: Furthermore, MHC II vaccines made from murine sarcoma, mammary carcinoma and melanoma cells activated tumor-specific CD4+ T cells and mediated rejection of established primary and metastatic mouse tumors, validating the MHC II vaccine concept in vivo in animal models [13–16].